FRANKFURT (dpa-AFX) - A turnaround in valuation by Morgan Stanley gave shares in Morphosys a strong boost on Friday. In early trading, the papers of the antibody specialist recovered 10 percent to 25.66 euros. But even last, they were still well above the reclaimed exponential 200-day line at plus 5 percent.

Analyst James Quigley gave up his "Underweight" with old target 13.50 euros and now votes "Overweight" with a price target of 35 euros. Morphosys "manifests" its success, he wrote, alluding to the Manifesto 2 study with the great hope Pelabresib. He gives the trial a good chance of success and then sees massive upside potential.

With estimated peak sales of $1.6 billion, Quigley, like other experts, sees the cancer drug pelabresib as a blockbuster candidate.

Morphosys is the best second-tier stock of the year on the SDax, up 85 percent. However, they are still a long way from their high for the year of 32.49 euros five weeks ago - not to mention the record of a good 148 euros set in 2000./ag/men